- ASSOCIATE DEAN FOR CLINICAL RESEARCH
- PROFESSOR Psychiatry
PHD, City University of New York Graduate Center
Dr. Mary Sano is Professor of Psychiatry and the Director of the Alzheimer's Disease Research at Mount Sinai School of Medicine. She is also the Director of Research and Development at the Bronx Veterans Administration Hospital. Currently she is the director of a national multi-center study known as CLASP (Cholesterol Lowering in Alzheimer's Disease to Slow Progression). Dr. Sano is a neuropsychologist by training and has been involved in designing and conducting clinical trials for Alzheimer's disease, Parkinson's disease, and mild cognitive impairment of aging. In 1989 she received the Florence and Herbert Irving Clinical Research Career Award to develop methodologies for the assessment of therapeutic agents in Alzheimer's disease. She directed the first ADCS multicenter trial of vitamin E and Selegiline, treatments which delayed the clinical progression of Alzheimer's disease and in 1998 she received the Veris Award for this study. In this study minority participation was more than double that of any other clinical trial for this disease. Her research interests are in clinical trial design and the impact of pharmacological treatments on the functional abilities of individuals with cognitive impairment.
At present she is the director of a new clinical study to determine if home based assessments can be used assess treatments for the prevention of cognitive loss and dementia. She has also developed tools to assess the economic impact of subtle cognitive changes in elderly subjects. Other areas of interest include the role of depression in cognitive impairment and dementia, womens' attitudes about prevention of memory loss, and measuring quality of life in diseases of aging. She is also the recipient of the Alzheimer Association grant to study Resveritrol, one of the active ingredients in red wine. Dr. Sano has also conducted work characterizing the cognitive impact of head injury, Sickle Cell disease, and mitochondrial disorders.
In the News
Dr. Sano shares tips to help reduce the risk and ease the symptoms of Alzheimer's in The Daily News feature The Daily Check Up. View the PDF.
Sano M. Tarenflurbil Mechanisms and Myths . Archives of Neurology 2010;.
Sano M, Egelko S, Ferris S, Kaye J, Hayes TL, Mundt JC, Donohue M, Walter S, Sun S, Sauceda-Cerda L. Pilot Study to Demonstrate the Feasibility of a Multi-Center Trial of Home-Based Assessment of People Over 75 Years Old . Alzheimr Diease and Related Disorders 2010;.
Schneider LS, Sano M, . Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer’s Dement 2009; 5: 388-97.
Jegebe AB, Rosado-Rivera D, Bauman WA, Cardozo CP, Sano M, Moyer JM, Brooks M, Wecht JM. Cognitive performance in hypotensive persons with spinal cord injury. Clin Auton Res 2009;.
Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachuriin SO, Seely L, Hung D, Dimebon Investigators . Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Lancet 2008; 372: 207-15.
Sano M, Jacobs D, Andrews H, Bell K, Graff-Radford N, Lucas J, Rabins P, Bolla K, Tsai WY, Cross P, Andrews K, Costa R, Xiaodong L. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics. Clin. Trials 2008; 5: 523-33.
Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyke CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008; 300: 1774-83.
Van Dyk K, Sano M. The Impact of Nutrition on Cognition in the Elderly. Neurochemical Research 2007; 32(4-5): 893-904.
Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ. Alzheimer's Disease Cooperative Study Group. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord 2006; 20(4): 232-41.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study New England Journal of Medicine 1997; 24(336): 1216-22.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Sano during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Eisai Inc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.